In summary, we have constructed a mathematical model of a solid tumour response to CAR-T cells with dual targets: one of them recognising a tumour antigen and the other recognising an off-tumour antigen present in normal cells such as CD19+ B-cells. This evidence concerns the gene CD19 and neoplasm.